Literature DB >> 31261238

Erythropoietin induces synaptogenesis and neurite repair after hypoxia ischemia-mediated brain injury in neonatal rats.

Tao Xiong1,2,3, Xiaoyan Yang1,2, Yi Qu1,2, Hongju Chen1,2, Yan Yue1,2, Huiqin Wang1,2, Fengyan Zhao1,2,3, Shiping Li1,2, Rong Zou1,2, Li Zhang1,2, Dezhi Mu1,2.   

Abstract

The memory dysfunction is one of the disastrous outcomes for perinatal hypoxia ischemia. Erythropoietin (EPO) has been demonstrated as a neuroprotective agent with multiple effects in a series of neurological diseases. We hypothesized that disruption of neural network including synapses and neurites would contribute to memory dysfunction induced by hypoxia ischemia. The aim of the present study was to elucidate the involvement of EPO on synaptogenesis and neurite repair following perinatal hypoxia ischemia. Using a neonatal hypoxia ischemia rat model, we found that EPO rescued hypoxia ischemia-induced decrease of synaptic proteins including Synapsin1 and PSD95 rather than GluR1 in the cortex and hippocampus. In addition, EPO reduced the expression of APP (an axonal injury marker), induced the expression of microtubule-associated protein MAP-2 (a dendritic marker), and restored axonal density after hypoxia ischemia. These changes contributed to improving electrophysiological properties of synapses and spatial memory performance. In summary, our data revealed an important role of EPO in synaptogenesis and neurite repair, providing a new insight into cellular mechanisms underlying cognitive and memory dysfunction associated with perinatal hypoxia ischemia.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31261238     DOI: 10.1097/WNR.0000000000001285

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  6 in total

Review 1.  Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.

Authors:  Kenneth Maiese
Journal:  Expert Rev Clin Pharmacol       Date:  2020-01-03       Impact factor: 5.045

2.  Mitochondrial Metabolism as Target of the Neuroprotective Role of Erythropoietin in Parkinson's Disease.

Authors:  Federica Rey; Sara Ottolenghi; Toniella Giallongo; Alice Balsari; Carla Martinelli; Robert Rey; Raffaele Allevi; Anna Maria Di Giulio; Gian Vincenzo Zuccotti; Serena Mazzucchelli; Roberta Foresti; Michele Samaja; Stephana Carelli
Journal:  Antioxidants (Basel)       Date:  2021-01-15

Review 3.  The Effect of Erythropoietin and Its Derivatives on Ischemic Stroke Therapy: A Comprehensive Review.

Authors:  Yuanyuan Ma; Zhiyuan Zhou; Guo-Yuan Yang; Jing Ding; Xin Wang
Journal:  Front Pharmacol       Date:  2022-02-17       Impact factor: 5.810

Review 4.  Considerations about Hypoxic Changes in Neuraxis Tissue Injuries and Recovery.

Authors:  Simona Isabelle Stoica; Coralia Bleotu; Vlad Ciobanu; Anca Mirela Ionescu; Irina Albadi; Gelu Onose; Constantin Munteanu
Journal:  Biomedicines       Date:  2022-02-18

5.  Further Evidence of Neuroprotective Effects of Recombinant Human Erythropoietin and Growth Hormone in Hypoxic Brain Injury in Neonatal Mice.

Authors:  Simon Klepper; Susan Jung; Lara Dittmann; Carol I Geppert; Arnd Hartmann; Nicole Beier; Regina Trollmann
Journal:  Int J Mol Sci       Date:  2022-08-04       Impact factor: 6.208

Review 6.  Thiamine as a Possible Neuroprotective Strategy in Neonatal Hypoxic-Ischemic Encephalopathy.

Authors:  Gian Pietro Sechi; Flaminia Bardanzellu; Maria Cristina Pintus; Maria Margherita Sechi; Maria Antonietta Marcialis; Vassilios Fanos
Journal:  Antioxidants (Basel)       Date:  2021-12-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.